Ansa Biotechnologies’ CEO Daniel Lin-Arlow’s passion is helping scientists do their job faster and deliver their innovation to the world. His latest solution? Enzymatic DNA synthesis. DNA writing is ...

Genetic medicines R&D is making strides with more complex DNA molecules. While these long sequences of synthetic DNA are key for developing gene and cell therapies as well as antibodies and other ...

Last year, during the Global Synthetic Biology (SynBioBeta) conference, Ansa Biotechnologies’ CEO Jason Gammack introduced attendees to the company’s first product—600 bp synthetic DNA constructs.

Ansa Biotechnologies Secures $54.4 Million in Series B Financing to Redefine How Scientists Access Synthetic DNA with Industry’s First Guaranteed On-Time Service Funding enables company to scale its ...

Company is first to deliver ultra-long, fully verified DNA in less than 25 days, backed by the industry’s only on-time guarantee Ansa Biotechnologies, the trusted partner for DNA synthesis, today ...

NEW YORK--(BUSINESS WIRE)--Ansa Capital, a new venture firm, today announced a $100 million initial raise of its debut fund that will focus on emerging growth stage companies. The fund’s initial ...